Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model

[1]  R. Cole,et al.  Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model , 2013, BMC Research Notes.

[2]  D. Sabatini,et al.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.

[3]  J. Geschwind,et al.  Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. , 2012, Radiology.

[4]  R. Hamanaka,et al.  Targeting glucose metabolism for cancer therapy , 2012, The Journal of experimental medicine.

[5]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[6]  C. Dang,et al.  Therapeutic targeting of cancer cell metabolism , 2011, Journal of Molecular Medicine.

[7]  R. Loffroy,et al.  3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. , 2010, Current pharmaceutical biotechnology.

[8]  J. Geschwind,et al.  3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. , 2010, Anticancer research.

[9]  V. Bhardwaj,et al.  Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. , 2010, Anticancer research.

[10]  A. Casini,et al.  Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS. , 2010, Journal of analytical atomic spectrometry.

[11]  R. Cole,et al.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. , 2009, Anticancer research.

[12]  J. Pawliszyn,et al.  Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method. , 2009, Journal of pharmaceutical and biomedical analysis.

[13]  Laurent Schwartz,et al.  Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. , 2009, Anticancer research.

[14]  W. Evans,et al.  Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. , 2009, Blood.

[15]  A. Galina,et al.  Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. , 2009, The Biochemical journal.

[16]  R. Wahl,et al.  Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study , 2008, Journal of Pharmacology and Experimental Therapeutics.

[17]  P. Pedersen,et al.  Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma , 2004, Expert review of anticancer therapy.

[18]  P. Pedersen,et al.  Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. , 2002, Cancer research.

[19]  P. Pedersen,et al.  Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. , 2001, Cancer letters.

[20]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[21]  C. Georgiades,et al.  Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. , 2007, Journal of vascular and interventional radiology : JVIR.

[22]  V. Neuhoff,et al.  Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G‐250 and R‐250 , 1988, Electrophoresis.